Adherence to chronic Hepatitis B (HBV) treatment and regular follow-up visits is essential for preventing dangerous complications, yet adherence rates in Vietnam remain low due to barriers in patient awareness and geographic conditions. Digital health solutions, particularly mobile applications, have shown potential as tools for supporting patients in proactive disease management. The HBVCare mobile application was developed to provide features such as medication reminders, storage of lab results, and health education to improve treatment adherence and clinical outcomes. The investigators are conducting a multicenter, randomized controlled trial at Hoang Long Clinic and Hanoi Medical University Hospital to evaluate the effectiveness of HBVCare. Patients are randomized into either a control group receiving standard care and an intervention group using the HBVCare app, with patient adherence and related factors assessed after three months of treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
70
Using the smartphone application HBVCare (with detailed instructions provided during recruitment)
Hanoi Medical University Hospital
Hanoi, Vietnam
RECRUITINGInstitute of Gastroenterology and Hepatology
Hanoi, Vietnam
RECRUITINGProportion of patients with good treatment adherence at 3 months
Patients achieved a high level of adherence to antiviral medication (25 points on MARS-5 score) and follow-up schedules (attend the clinical follow-up within 1 week of the pre-specified schedule) as recorded through the HBVCare application.
Time frame: 3 months after recruitment
Changes in Clinical Symptoms
Assessment of 8 subjective symptoms associated with chronic Hepatitis B (fatigue / tiredness, Skin or mucosal hemorrhage, loss of appetite, ascites, nausea / vomiting, pain or discomfort in the liver area, jaundice / discolored urine, peripheral edema). Symptom progression was evaluated over a 3-month follow-up period based on patient-reported outcomes: improvement, no change, worsening, new onset, or absence of symptoms.
Time frame: Baseline and 3 months after recruitment
Mean Usability Metric for User Experience-Lite (UMUX-Lite) Score at 3 Months
Evaluation of the overall perceived usability and usefulness of the HBVCare digital platform. The Usability Metric for User Experience-Lite (UMUX-Lite) consists of two items (the app is easy to use, the app meets my requirements) measured on a 7-point Likert scale (total of 14 points, higher scores indicate better perceived usability and a more positive user experience).
Time frame: 3 months after recruitment
Mean Patient Satisfaction Scores for HBVCare App Features at 3 Months
Assessment of user satisfaction with 5 specific app features: clinical data storage, medication/follow-up reminders, health education, symptom/adherence surveys, and reporting graphs. Each feature is rated on a 5-point Likert scale (1 = Very Dissatisfied, 5 = Very Satisfied). Higher scores indicate higher levels of satisfaction with the specific feature.
Time frame: 3 months after recruitment
Mean Change from Baseline in concentrations of Serum Liver Enzyme Levels (Units per Liter) at 3 Months.
Liver function test results for evaluating hepatic inflammation, including concentrations of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and Gamma-glutamyl Transferase (GGT). Unit of Measure: Units per Liter (U/L).
Time frame: Baseline and 3 months after recruitment
Mean Change from Baseline in concentrations of Serum Bilirubin Levels (Milligrams per deciliter) at 3 Months
Evaluation of bilirubin processing, including Total Bilirubin and Direct Bilirubin. Unit of Measure: Milligrams per deciliter (mg/dL)
Time frame: Baseline and 3 months after recruitment
Mean Change from Baseline in concentration of Serum Albumin (Grams per deciliter) at 3 Months.
Assessment of hepatic synthetic function by measuring the concentration of serum albumin. Unit of Measure: Grams per deciliter (g/dL).
Time frame: Baseline and 3 months after recruitment
Mean Change from Baseline in Platelet Count (Thousands per microliter) at 3 Months.
Measurement of the number of circulating platelets to monitor for portal hypertension or bone marrow suppression. Unit of Measure: Thousands per microliter (10\^3/μL).
Time frame: Baseline and 3 months after recruitment
Mean Change from Baseline in International Normalized Ratio (INR) at 3 Months.
Measurement of a standardized measure of prothrombin time called International Normalized Ratio (INR) to evaluate blood coagulation and liver synthetic function. Unit of Measure: Ratio (Unitless).
Time frame: Baseline and 3 months after recruitment
Mean Change from Baseline in Serum Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Viral Load in International Units per milliliter at 3 Months
Quantitative measurement of Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) to evaluate the level of viral replication. Unit of Measure: International Units per milliliter (IU/mL)
Time frame: Baseline and 3 months after recruitment
Mean Change from Baseline in Quantitative Hepatitis B Surface Antigen (qHBsAg) in International Units per milliliter (IU/mL) at 3 Months
Evaluation of the change in serum concentration of Hepatitis B Surface Antigen (HBsAg). Unit of Measure: International Units per milliliter (IU/mL)
Time frame: Baseline and 3 months after recruitment
Number of Participants Achieving Hepatitis B envelope Antigen (HBeAg) Seroclearance at 3 Months
Number of participants who transit from Hepatitis B envelope Antigen (HBeAg)-positive at baseline to HBeAg-negative at the 3-month follow-up. Unit of Measure: Number of participants
Time frame: Baseline and 3 months after recruitment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.